Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03106077
Title Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Mirvetuximab Soravtansine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.